|
J Biol Chem, Vol. 275, Issue 11, 7902-7909, March 17, 2000
The Human Growth Hormone Gene Cluster Locus Control Region
Supports Position-independent Pituitary- and Placenta-specific
Expression in the Transgenic Mouse*
Yuhua
Su ,
Stephen A.
Liebhaber §, and
Nancy E.
Cooke ¶
From the Departments of Medicine and Genetics, and
the § Howard Hughes Medical Institute, University of
Pennsylvania, Philadelphia, Pennsylvania 19104
 |
ABSTRACT |
The human growth hormone (hGH) cluster contains
five genes. The hGH-N gene is predominantly expressed in pituitary
somatotropes, whereas the remaining four genes, the chorionic
somatomammotropin genes (hCS-L, hCS-A, and hCS-B) and hGH-V, are
expressed selectively in the placenta. In contrast, the mouse genome
contains a single pituitary-specific GH gene and lacks any GH-related
CS genes. Activation of the hGH transgene in the mouse is dependent on
its linkage to a previously described locus control region (LCR)
located 15 to 32 kilobases upstream of the hGH cluster. The
sporadic, nonreproducible expression of hCS transgenes lacking the LCR
suggests that they may be dependent on hGH LCR activity as well. To
determine whether the hCS genes could be expressed with appropriate
placental specificity, a series of five transgenic mouse lines carrying an 87-kilobase human genomic insert encompassing the majority of the
hGH gene cluster and the entire contiguous LCR was established. All of
the hGH cluster genes were appropriately expressed in each of these
lines. High level expression of hGH was restricted to the pituitary and
hCS to the labyrinthine layer of the placenta. The expression of the GH
cluster genes in their respective tissues paralleled transgene copy
numbers irrespective of the transgene insertion site in the host mouse
genome. These studies have extended the utility of the transgenic mouse
model for the analysis of the full spectrum of hGH gene cluster
activation. Further, they support a role for the hGH LCR in placental
hCS, as well as pituitary hGH gene activation, and expression.
 |
INTRODUCTION |
The human growth hormone
(hGH)1 gene family is encoded
within a 48-kilobase (kb) cluster on chromosome 17q22-24. It contains five genes that share greater than 94% sequence identity (1, 2). hGH-N
is selectively expressed in the somatotrope and lactosomatotrope cells
of the anterior pituitary, whereas the other four genes, hCS-L, hCS-A,
hGH-V, and hCS-B, are expressed in the syncytiotrophoblastic layer of
the mid- to late gestational placenta (3-5). Among the placental
genes, hCS-A and hCS-B are highly expressed, whereas hCS-L and hGH-V
are expressed at trace levels (6). The mutually exclusive tissue
specificities and distinctive developmental controls of the closely
spaced and structurally related hGH and hCS genes make the hGH gene
cluster a highly informative model system for the study of gene
expression in mammalian development.
Activation and expression of genes in their native chromatin context
reflect the combined actions of multiple determinants. The most well
characterized cis-acting determinants of gene expression are
those located in close proximity to the respective promoter. There are
a number of well defined and functionally characterized promoter
proximal determinants critical to the expression of hGH-N. Among these
are a pair of binding sites for the tissue-restricted POU-homeodomain
protein, Pit-1/GHF-1 (7), and a binding site for the more widely
expressed zinc-finger protein factor (Zn-15) (8). In the case of the
hGH-N gene these proximal promoter elements, necessary for gene
expression in cell transfection assays, are insufficient to mediate
in vivo, tissue-specific expression in transgenic mouse
lines (9-11). This observation points to the existence of determinants
located at a greater distance from the hGH gene that are essential to
the establishment of a transcriptionally active chromatin domain. A set
of such determinants, located from 14.5 to 32 kb 5' to the hGH-N gene
promoter, were identified by DNaseI hypersensitivity (HS) mapping of
chromatin from expressing tissues. The closely spaced HSI and HSII are
specific to pituitary chromatin, HSIII and HSV are shared by pituitary
and placental chromatin, and HSIV is specific to placental chromatin.
When linked to the hGH-N gene, the full set of determinants directs
high level, position-independent, somatotrope-specific expression of
the hGH-N gene in transgenic mice in a consistent and predictable
manner (10, 11). The ability of these determinants to overcome site of
integration effects on the hGH-N gene fulfills the functional criteria
for a locus control region (LCR). These criteria were initially defined
for the human -globin LCR (12-15) and subsequently for a small
group of additional gene systems including the chicken lysozyme LCR
(16, 17) and the LCR for the human red and green visual pigment genes
(18, 19). A similar dependence of the placental genes in the hGH gene
cluster on LCR activation has not been demonstrated.
The hCS-A transgene, with extensive 5'- and 3'-flanking sequences, is
either not expressed at all or is expressed at low and unpredictable
levels in the mouse placenta (10). These observations might reflect two
alternative, or coexisting, mechanisms: 1) the mouse, which lacks
CS-like genes, is unable to support hCS transgene expression in the
placenta because of a species-specific array of placental transcription
factors poorly suited for hCS gene activation or 2) the consistent
activation of the hCS transgene is dependent on linkage to the hGH LCR.
This second possibility is supported by our previous observation that a
specific subset of hGH LCR HS form in the chromatin of primary human
placental syncytiotrophoblast nuclei (10). In the present report we
have isolated a human genomic clone that contains the entire LCR as well as much of the contiguous gene cluster encompassing both hGH-N and
hCS-A. By introducing this 87-kb transgene into the mouse genome we are
able to document the competence of the mouse transgenic model to
reliably support appropriate expression of the hGH gene cluster in both
the pituitary and the placenta. These data support the role of the hGH
LCR in activation of both hGH and hCS gene expression.
 |
EXPERIMENTAL PROCEDURES |
Enzymes, Probes, and Primers
Restriction and modification enzymes were purchased from New
England Biolabs, Promega, Life Technologies, Inc., and Roche Molecular
Biochemicals. RNAzol B RNA isolation solvent was purchased from
Tel-Test, Inc; the Oligotex mRNA kit was from Qiagen Inc; [ -32P]dCTP, [ -32P]ATP (10 mCi/ml), and [ -33P]UTP (10mCi/m) were from Amersham
Pharmacia Biotech, and Elutip columns were from Schleicher & Schuell.
Genomic and cDNA fragments were labeled by
[ -32P]dCTP with a Random-Primed DNA Labeling Kit
(Roche Molecular Biochemicals) and purified on a G-50 spin column.
Oligonucleotide probes were labeled at their 5'-terminus by
[ -32P]ATP with T4 polynucleotide kinase.
Antisense and sense riboprobes were labeled with
[ -33P]UTP by T7- or SP6-mediated transcription of
respective templates.
The hGH-N genomic probe was a 1.37-kb SmaI fragment
(coordinates 494 to 876 bp, relative to the hGH-N transcription
initiation site) (10); the HSI and -II genomic probe was a 1.6-kb
BglII fragment (coordinates 14.56 to 16.16 kb) (11); and
the HSIV probe was a 2.38-kb SmaI fragment (coordinates
31.23 to 28.85; GenBankTM Accession number AC005803).
The MX probe, which detects the unique sequence 3'-flanking region of
the m -globin gene, was released as a 1.3-kb BamHI
fragment from pMX plasmid (20). The mouse rPL32 cDNA probe was
released as a 0.32-kb EcoRI and HindIII fragment
from the rpL32 plasmid (21). The P1 vector 3'-end probe was a 0.23-kb
BglI segment corresponding to position 15.25-15.65 kb in
the P1 vector. All oligos used as hybridization probes or as primers
were synthesized by the Nucleic Acid and Protein Research Core Facility
of Children's Hospital of Philadelphia or by Life Technologies, Inc.
All primer sequences are listed in Table
I.
Screening the Human Genomic P1 Library and Mapping the P1
Clone
A human genomic P1 library (Genome Systems, PAD10SacBII vector)
was screened with a primer pair (CSA(E) primers, Table I) corresponding
to the hCS-A gene 3'-enhancer and a second primer pair (HSV primers)
corresponding HSV (Table I). A doubly positive clone, P1 6057, was
obtained. P1 6057 was mapped by Southern blot analysis of complete
restriction enzyme digestions (see "Results") and by indirect end
labeling of partial digestions. In the latter case, the DNA was
linearized with NotI and subsequently partially digested
with ClaI or EcoRI. Digests were
electrophoresed on pulsed field gels (FIGE Mapper Electrophoresis
System), DNA was transferred to Zetabind, and the membranes were
incubated with a 32P-labeled oligomer corresponding to the
T7 site in the P1 vector or to a probe corresponding to the 3'-end of
linearized P1 6057. This mapping served to screen for any deletions or
rearrangements in the insert compared with the sequence
(GenBankTM AC005803) or the known restriction map of the
LCR and gene cluster (1, 10).
Generation and Analysis of P1 Transgenic Mice
P1 6057 plasmid DNA was linearized at the NotI site
(Fig. 1), purified by Elutip (Schleicher & Schuell), adjusted to 2 ng/µl in 10 mM Tris-HCl, pH 7.6, 0.1 mM EDTA,
and microinjected into the male pronucleus of fertilized mouse eggs
(University of Pennsylvania Transgenic and Chimeric Mouse Core).
Positive founders were identified by dot blot analysis of tail DNA
using the hGH-N probe. The transgene was mapped in F1 progeny, and the
transgene copy number for each line was determined by Southern blot
analysis (described in "Results").
Hybridization Analyses
Southern Blotting--
7-10 µg of restriction enzyme-digested
mouse tail DNA was fractionated on 0.8% agarose gels. This was
transferred to a Zetabind nylon membrane with 10× SSC (1.5 M NaCl, 0.15 M sodium citrate), UV cross-linked
to the membrane, and prehybridized (0.5 M
NaPO4, pH 7.2, 7% SDS, 1% bovine serum albumin, 0.1 mM EDTA, and 200 µg/ml denatured salmon sperm DNA) at
65 °C overnight. The membrane was subsequently hybridized at
65 °C overnight with 2 × 106 cpm/ml of probe,
washed twice with 0.5× SSC, 0.1% SDS, and washed a third time with
0.1× SSC, 0.1% SDS. The washed blots were exposed to XAR-5 film
(Kodak), and signals were quantified by phosphorimager analysis.
Northern Blotting--
Total RNA was extracted from various
organs with RNAzol, and poly(A)+ RNA was extracted from
placenta with an Oligotex mRNA Mini Kit. 5-10 µg of total RNA or
poly(A)+ mRNA were denatured at 65 °C, fractionated
on 1% agarose gels containing 2.2 M formaldehyde in 0.1 M MOPS, pH 7.0, 0.6 M sodium acetate, 0.1 M EDTA, pH 8.0, and transferred to Zetabind nylon membrane
in 10× SSC. After UV cross-linking, the blot was prehybridized in 50%
formamide, 5× SSC, 5× Denhardt's solution, 0.1% SDS at 42 °C for
1-5 h. The membrane was subsequently hybridized by adding 1-2 × 106 cpm/ml of the indicated probe at 42 °C overnight and
washed (2× SSC, 0.1% SDS, then 1× SSC, 0.1% SDS, and finally 0.1×
SSC, 0.1% SDS) at room temperature to 65 °C.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
hGH-N expression in the pituitary was documented and quantified
relative to endogenous mGH mRNA by the RT-PCR approach generating an hGH-N to mGH mRNA ratio as described previously (10). Briefly, reverse transcription and subsequent PCR were carried out beginning with 0.2-0.5 µg of total RNA using primers corresponding to regions perfectly conserved between mGH and hGH (mhGH primer set, Table I).
After 30 cycles of PCR the 3'-end-labeled cDNA products were digested with BstNI to generate fragments specific to hGH-N
and mGH mRNAs. Intensities of the two bands were compared by
phosphorimager analyses.
The RT-PCR analysis of hCS-A expression was performed with the hGHNCSA
I primer set (Table I). These primers annealed to both hCS-A and hGH-N
mRNAs. The 5'-end-labeled cDNA products were cut with
BamHI to generate a 104-bp end-labeled hCS-A cDNA band.
The nested RT-PCR analysis for distinguishing hGH-N and hGH-V mRNAs
was performed by using primers hGH-N/V5' A and hGH-N 3' and a nested
[ -32P]ATP-labeled hGH-N/V5' B. These primers
correspond to the regions conserved between hGH-N and hGH-V but do not
anneal to hCS-A or hCS-L. After RT with hGH-N 3' and 3 cycles of cold
PCR with hGH-N/V5' A and hGH-N 3', [ -32P]ATP-labeled
hGH-N/V5' B was added before the final 27 cycles of PCR. PCR was
carried out with 2.5 units of Taq DNA polymerase at 1 mM Mg2+. The temperatures for annealing,
elongation, and denaturation were 55, 72, and 94 °C, respectively.
The 5'-end-labeled PCR products were digested with TaqI; a
specific 38-bp hGH-N end-labeled cDNA fragment and a specific
120-bp hGH-V fragment were expected. The samples were analyzed on 8%
denaturing polyacrylamide gels.
The RT-PCR analyses for comparing hCS-A and hGH-N expression in the
placenta were performed by using the hGHNCSA II primer set followed by
a nested amplification between hGHNCSA II 5' and 32P-labeled hGHNCSA II 3' B. The 3'-end-labeled products
were cut with HhaI and fractionated on 6% polyacrylamide
gels to generate 141-bp hGH-N- and 130-bp hCS-A-specific fragments.
Intensities of these two bands were compared by phosphorimager analysis.
In Situ Hybridization
Generation of hCS-A cDNA--
A pair of primers (hcs
cDNA 5' and hcs cDNA 3'; Table I) were used to amplify a 614-bp
hCS-A cDNA fragment extending from coordinates 114 to 738 of the
hCS-A cDNA clone (pG12F extends from 102 to 654 nucleotides of
hCS-A cDNA plus the 3'-UTR and 77 base poly(A) tail (6)). PCR
products were purified by recovery from the gel and ligation into
pGEM-T easy vector (Promega).
Generation of Riboprobes--
The subcloned hCS-A cDNA
plasmid (641 pGEM-T-A) was linearized with SpeI (for T7
transcription) or NcoI (for Sp6 transcription). The
linearized plasmids were transcribed in vitro using
MEGAshortscript T7 Kit (for the antisense probe) or Sp6 Kit (for sense
probe), in the presence of [ -33P]UTP.
In Situ Hybridization--
Placentas were collected from mouse
embryos generated by crossing an hGH P1 line 813I male with a CD-1
female. The mother was euthanized at embryonic day 16 and the placentas
were fixed in 4% paraformaldehyde in PBS (pH 7.2) at 4 °C
overnight. Genotypes were determined by dot blot analyses of embryonic
tissues. Placentas of the transgenic and wild-type mice were embedded
in paraffin, and 5-µm sections were prepared and treated for in
situ hybridization as described previously with minor
modifications (22). Briefly, wax was removed, and the sections were
rehydrated, fixed with 4% paraformaldehyde in PBS (pH 7.2) for 20 min,
and washed twice with PBS for 5 min each. The sections were treated
with 20 µg/ml proteinase K in 50 mM Tris-HCl, pH 8.0, 5 mM EDTA for 7.5 min, washed with PBS, and fixed again in
4% paraformaldehyde for 5 min. After washing with PBS, the slides were
treated in 0.1 M triethanolamine for 5 min followed by
incubation in 0.25% acetic anhydride in 0.1 M
triethanolamine for 5 min. Following washing with 2× SSC, the slides
were incubated overnight with 4 × 106 cpm of probe in
100 µl of hybridization buffer (40% formamide, 0.48 M
NaCl, 8 mM Tris-HCl, pH 7.5, 1.6 mM EDTA, 0.8×
Denhardt's solution, 0.4 mg/ml yeast tRNA, 80 µg/ml
poly(A)+ RNA, and 10% dextran sulfate) overnight at
65 °C. The slides were washed with 5× SSC for 10 min at 50 °C,
then in 50% formamide, 2× SSC for 20 min at 65 °C, next in RNase
buffer (0.3 M NaCl, 10 mM Tris-HCl pH 8.0, 5 mM EDTA) for 30 min at 37 °C, and then digested with
RNase A (50 µg/ml) in the same buffer for 30 min at 37 °C. Finally
the slides were washed with RNase buffer, 50% formamide in 2× SSC,
2× SSC alone, and 0.1× SSC. The slides were dehydrated and exposed to
emulsion for about 2 weeks and then developed and stained with
hematoxylin and eosin. Bright field and dark field micrographs were
generated using a Nikon Microphot-FX microscope.
 |
RESULTS |
Isolation and Mapping of a P1 Clone Encompassing the hGH Locus and
Its Contiguous LCR--
A genomic fragment containing the entire hGH
LCR and the majority of the contiguous hGH gene cluster was isolated
from a human genomic P1 library. The library was screened with
amplimers specific for the region immediately 5' to HSV of the LCR and
a second primer set specific for a site 3 kb 3' to the hCS-A gene. A
clone positive with both probes, P1 6057, was isolated and named
"hGH/P1." The restriction map of this clone was compared with the
known genomic structure (1, 10). The hGH-N probe, which
cross-hybridizes to each of the genes in the cluster, identified unique
10.5 and 7.8 kb BglII bands corresponding to hCS-A and hCS-L
and a more intense 2.6-kb band containing the two identically sized
fragments with the hGH-N and hGH-V genes, respectively (Fig.
1B, right). Missing
was the most 3'-gene in the cluster, hCS-B, which would have been
present on a 3-kb BglII fragment. The HSI and -II probe detected the expected 1.6-kb BglII fragment (Fig.
1B, middle), and the HSIV probe hybridized to the
expected 22 kb EcoRI band encompassing HSIII, HSIV, and HSV
(Fig. 1B, left). Additional mapping of the hGH/P1
insert DNA by complete and partial digestions failed to reveal any
rearrangements or deletions when compared with the genomic structure
(data not shown). The orientation of the insert relative to the vector
(Fig. 1C) was established by demonstrating that the
vector-derived T7 polymerase segment and the HSIV site were located on
the same ClaI restriction fragment (data not shown). Thus
the 87-kb P1 6057 (hGH/P1) insert spanned coordinates 45.8 to 40.6 kb
of the hGH locus (hGH-N transcription start site as coordinate 1) and
contained all five HS sites of the LCR and the contiguous hGH-N, hCS-L,
hCS-A, and hGH-V genes (Fig. 1, A and
C).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of a P1 clone, hGH/P1,
containing the hGH gene cluster and contiguous LCR. A,
hGH/P1 map. A linear diagram of the human genomic insert in the hGH/P1
clone is shown. The positions of each of the four genes of the hGH gene
cluster encompassed by the insert (hGH-N, hCS-L, hCS-A, and hGH-V) are
represented as black boxes, and the positions of each of the
HS constituting the hGH LCR are indicated above the line
(labeled vertical arrows). The coordinates (kb) are
referenced to the 5'-terminus of the cluster (hGH-N transcription
initiation site = 0). The P1 vector is shown schematically as a
solid black line. The positions of the 5'- and 3'-amplicons
used to identify the hGH/P1 clone are indicated (HSV and CSA(E) in
Table I) as are the EcoRI
(E) and BglII (B) sites used in
mapping (labeled arrows below the line). Restriction
fragment sizes are also indicated. B, Southern blot analysis
of the hGH/P1 insert. The hGH/P1 plasmid was digested with
EcoRI or BglII (for diagram of restriction sites
see A). Hybridization with an hGH probe that hybridizes to
all four genes in the cluster resulted in BglII bands
corresponding to hCS-A (10.53 kb), hCS-L (7.79 kb), hGH-N (2.58 kb),
and hGH-V (2.50 kb). Rehybridizing with an HSI and -II probe revealed
the expected 1.6-kb BglII fragment. An appropriately sized
22-kb fragment containing HSIII, HSIV, and HSV was detected following
hybridization of the EcoRI digestion with a probe
corresponding to HSIV. C, map of the hGH/P1 plasmid. The
orientation of the hGH cluster in the P1-based plasmid and the position
of the NotI site used for linearization ("Linearization
site") are shown. The positions of the four genes of the hGH cluster
in the hGH/P1 insert and the positions of the five LCR HS are
indicated.
|
|
Generation of hGH/P1 Transgenic Mouse Lines--
The hGH/P1
plasmid was mapped for rare cutting endonucleases sites to identify a
unique site for linearization prior to zygotic microinjection.
NotI, SalI, and SfiI were tested
because each cleaves a single site adjacent to the P1 vector cloning
site (23). The banding pattern of the restriction digestions on 1%
agarose pulsed field gels demonstrated that the insert contained two
SfiI sites and one SalI site but lacked a
NotI site (data not shown). NotI was therefore
used for linearization (Fig. 1C). The size of the
NotI-linearized plasmid was consistent with the 87-kb
genomic insert size (see above). The linearized hGH/P1 plasmid was
microninjected into fertilized mouse oocytes, and five transgenic
founders were obtained: 809C, 809F, 811B, 811D, and 813I. Each founder
was crossed with a CD1 mate to generate an F1 transgenic. The integrity
and copy number of the transgene in each line was determined by
Southern blot of F1 tail DNA. Membranes were sequentially hybridized
with probes for hGH-N, HSI, -II, and HSIV. Fig.
2 shows a representative Southern blot
using the 1.37-kb hGH-N probe. In all cases, the bands predicted by the
map (Fig. 1) were obtained. The transgene copy number was estimated for
each line by normalizing the transgene signals to a loading control,
the mouse -globin probe (m-MX), and to human genomic DNA. The
transgene copy numbers determined in this way ranged from 2 to 19 (Fig.
2).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2.
Structural analysis of the hGH/P1
transgenes. Southern blot analysis of F1 genomic tail DNA from
each of the five hGH/P1 lines was done. DNA was digested with
BglII and hybridized with an hGH-N probe. Control DNAs were
isolated from normal human diploid fibroblasts and from tail DNA of a
wild-type mouse. The diagram below the autoradiograph shows the
relevant BglII sites and fragments. Each of the four genes
in the transgene cluster are represented by solid rectangles
and the hCS-B gene, which is not encompassed in the hGH/P1 transgene,
is indicated by a gray rectangle. The cluster was intact in
each transgenic line as indicated by the presence of three
appropriately sized bands at corresponding intensities in each line.
The transgene copy number was estimated by normalizing the signals to
mouse -globin gene (m-MX) used as the DNA loading control and
comparing this normalized signal to the human genomic DNA sample. These
values are indicated below the corresponding lanes.
|
|
Expression of the hGH/P1 Transgene in the Mouse
Pituitary--
In previous studies we documented that the hGH-N
gene is appropriately expressed in the pituitaries of transgenic mice
when linked to its contiguous LCR (10). To confirm and extend this observation, expression of the hGH cluster containing the hGH-N gene as
well as the linked and placentally expressed hCS-L, hCS-A, and hGH-V
genes was analyzed. RNA was isolated from the pituitaries of adult F1
transgenic mice from each of the five hGH/P1 lines. These samples were
analyzed for hGH-N, hCS, and hGH-V mRNAs. hGH-N mRNA was
identified and quantified relative to endogenous mGH mRNA using an
RT-PCR co-amplification assay (10) (Fig.
3A). This approach
co-amplifies hGH and mGH as identically sized fragments that can be
subsequently differentiated and quantified by restriction analysis (the
primers do not amplify hGH-V or hCS). The analyses of all five
transgenic mouse lines revealed the expected three cDNA fragments;
two (170 and 125 bp) corresponding to the two major splice products of
the hGH transcript and the third (110 bp) corresponding to mGH
cDNA. The ratios of the hGH to mGH signals were quantified and
normalized to transgene copy number. The pituitary expression from the
hGH-N gene was consistent from line to line, varying less than 3-fold
(0.34-0.96) (Fig. 3A). This range of hGH-N transgene
expression was remarkably similar to that observed previously for the
LCR linked to the isolated hGH-N gene (10). This result demonstrated
reproducible, copy number-dependent expression of the hGH-N
gene from the 87-kb hGH P1 transgene.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Selective, copy number-dependent
expression of the hGH-N locus from the hGH/P1 transgene in mouse
pituitaries. The framed diagram to the right of each
autoradiograph indicates the RT-PCR approach used to detect, specify,
and quantify the respective mRNAs. In each case the end-labeled (*)
PCR product was digested with the indicated restriction enzyme to
differentiate between two co-amplified mRNA species. A,
relative expression of hGH-N and mGH. hGH and mGH mRNAs were
co-amplified from hGH/P1 pituitary RNA samples using the mhGH primer
set (Table I). Digestion of the end-labeled cDNAs with
BstNI generated a strong 170-bp hGH-N cDNA band, a weak
125-bp alternatively spliced hGH-N band, and a 110-bp mGH cDNA band
in the pituitary sample from each line. Wild-type mouse pituitary
showed only the 110-bp mGH cDNA band, and mRNA from the
pituitary of the 149C mouse line (expressing an isolated hGH-N
transgene (10)) was used as positive control for hGH mRNA. The
levels of hGH-N mRNA normalized to mGH mRNA and to transgene
copy numbers (Fig. 2) are indicated below the respective lanes. This
value represents the level of expression from a single transgene copy
as a percentage of a single endogenous mGH gene. B,
selective expression of hGH-N but not hCS-A in the hGH/P1 transgenic
pituitary. The pituitary RNA samples were as in A with the
exception that RNA isolated from the placenta of the 809C line (Fig. 4)
was used as a positive control for hCS-A RNA. hGH-N and hCS-A RNAs were
co-amplified with the hGHNCSA I primer set (Table I) and were
distinguished by digestion with BanI (as shown to the
right). C, selective expression of hGH-N but not hGH-V in
the hGH/P1 transgenic pituitary. hGH-N and hGH-V RNAs were co-amplified
using the hGHN3' and hGHN/V5'A primers and then with a second, nested
and end-labeled 5'-hGHN/V5'B primer (Table I). The respective cDNAs
were distinguished by digestion with TaqI (as shown to the
right). The pituitary samples were as in A with
the exception that human placentas were used as positive controls for
the detection of hGH-V.
|
|
The genes in the hGH gene cluster are highly similar in structure and
yet are expressed in mutually exclusive tissue distributions, predominantly in the pituitary or the placenta. To determine whether this tissue specificity of expression from the hGH gene cluster is
maintained in the mouse model, the expression of hCS and hGH-V was
tested in the pituitary. RT-PCR was performed on transgenic pituitary
RNA using a pair of primers that were complementary to both hGH-N and
hCS-A mRNAs; the co-amplified cDNAs were then distinguished by
restriction digestions (Fig. 3B). In contrast to the strong
hGH-N signals in each sample, there was a complete absence of hCS-A
expression in all lines. The total lack of hCS-A expression was
confirmed using a technically independent hCS-specific nested RT-PCR
assay (data not shown). A similar RT-PCR approach designed to detect
ectopic expression of the placental hGH-V revealed total absence of
expression in transgenic mouse pituitaries from each of the five
transgenic lines (Fig. 3C). Expression of the hCS-L gene was
not tested, because the function of this gene has been lost during the
evolution of the cluster via multiple alternative splicing errors (24).
The high levels of hGH-N and absence of detectable expression of hGH-V
or hCS-A indicated that the genes in the hGH gene cluster were
expressed with appropriate tissue specificity in the pituitaries of all
five of the hGH/P1 lines.
Phenotype of the hGH/P1 Mouse Lines--
All five of the hGH/P1
transgenic mouse lines displayed normal fertility, fecundity, and
lifespan. Males and females from each line were weighed at intervals
starting at 3 weeks of age. Although there was minor variations in body
weight from line to line, only line 813I displayed a growth curve that
differed significantly from sex-matched wild-type littermates. The 813I
transgenic mice (both males and females) were approximately 10% larger
than the matched controls after 7 weeks of age. This difference did not increase with time. The normal body growth rate of all the remaining groups indicated that hGH expression from the P1 transgene was under
normal physiologic control and that no significant ectopic and/or
unregulated transgene expression was occurring in other tissues.
Transgene Expression in the Placenta--
In a previous study, we
had generated six mouse lines transgenic for a 15-kb HindIII
fragment encompassing the hCS-A gene along with 5.4 kb of contiguous
5'-flanking region and 7.2 kb of contiguous 3'-flanking region (10).
When assessed for expression in the placenta, only two of these lines
expressed hCS mRNA at clearly detectable levels, two at trace
levels, and two not at all (10). This lack of consistent transgene
expression suggested that the transgene was subject to site of
integration effects. To test the hypothesis that hGH LCR element(s)
might be necessary for consistent locus activation in the placenta,
gene expression was assessed in the placentas of fetuses from each of
the five lines carrying the hGH/P1 transgene. F1 transgenic mice from
each of the lines were crossed with wild-type mates to generate
embryonic day 18 and 19 fetuses. The genotype of each embryo was
determined by DNA dot blotting, and the corresponding placentas were
assessed for hCS-A transgene expression by an RT-PCR restriction
endonuclease assay as well as by Northern blot analyses (Fig.
4, A and B,
respectively). By RT-PCR, all five lines were positive for placental
expression of hCS-A mRNA. Of note, low levels of hGH-N mRNA
were also detected in all samples, but in each case these levels were
approximately 1% that of the hCS-A mRNA. The levels of hCS-A
expression in the placenta were quantified for each of the five lines
by Northern blot analysis. An hCS-A mRNA band was detected in
placental mRNA from each of the five lines (Fig. 4B).
The signal intensity quantified by phosphorimager was normalized to a
loading control signal and then divided by the transgene copy number.
These normalized hCS-A expression values were remarkably consistent
among four of the mouse lines (2-fold range). A fifth line, 809C line,
expressed hCS at a 10-fold higher level. Thus the hCS-A gene in the
hGH/P1 transgene was expressed in all lines irrespective of its site of
integration, and with the exception of line 809C, the levels of
expression were closely related to transgene copy number.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 4.
Selective, copy number-dependent
expression of hCS-A mRNA in the placentas of mice carrying the
hGH/P1 transgene. A, RT-PCR detection of hCS-A mRNA and
trace levels of hGH-N mRNA in hGH/P1 mouse placentas. hCS-A and
hGH-N mRNAs were reverse transcribed and co-amplified between the
hGHNCSA II 3'A and hGHNCSA II 5'-primers and then labeled by further
amplification with a second, end-labeled and nested 3'-primer (hGHNCSA
II 3'B) (Table I). The respective cDNA products were distinguished
by digestion with HhaI (as diagrammed to the
right of the autoradiograph). A strong hCS-A band (130 bp)
and a very faint hGH-N band (141 bp) were detected in the placental RNA
of each hGH/P1 mouse line. The relative expression of hGH-N to hCS-A is
represented as a percentage below the corresponding lanes. Control
mRNAs include placental RNA from mouse line 766I carrying an
isolated hGH-N transgene with targeted ectopic expression in the
placenta (F. Elefant, Y. Su, S. A. Liebhaber, and N. E. Cooke, manuscript in preparation) and line 484E carrying the isolated
hCS-A gene previously shown to be expressed in the placenta (10).
B, Northern blot analysis demonstrates copy
number-dependent expression of the hCS-A gene.
Poly(A)+ samples, corresponding to sources indicated above
each lane, were hybridized with a probe for hCS mRNA and then
stripped and rehybridized with a probe for mouse ribosomal protein L32
(mrpL32) mRNA as a loading control. The expression of hCS-A,
normalized for RNA loading and for transgene copy number are indicated
below the respective lanes.
|
|
The Ectopic Expression of the Transgenes in the Different
Tissues--
The above data demonstrated that hGH-N was selectively
expressed in the pituitary and hCS-A in the placentas of hGH/P1 mice. The possibility of ectopic expression of the GH cluster outside of the
pituitary or placenta was next investigated. By Northern blotting a
strong hGH mRNA signal was detected in the pituitary and a weaker
hCS mRNA signal in the placenta. In contrast, no signals were
obtained in any of multiple other tissues surveyed (a single exception
was a very weak signal in the testis of line 813I, the highest
transgene copy line) (data not shown). To assess ectopic expression at
a higher level of sensitivity, we carried out RT-PCR analyses with
three sets of primers specific for hGH-N, hCS-A, or -actin. A
representative study using line 809C is shown in Fig.
5. Strong signals were seen for hGH-N in
the pituitary. Low level expression of hGH-N was detected in the
placenta as observed previously. Similarly low levels were detected in
the brain in all lines and in the testis, ovary, and spleen in a subset of lines. A strong hCS-A signal was generated from placental RNA and
very low levels of expression were observed in the brain, testis, and
ovary of several lines. These data support specific and mutually
exclusive tissue specificities for the hGH and hCS loci in the context
of the hGH/P1 transgene.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 5.
RT-PCR survey for expression of the hGH/P1
transgene in various tissues. The autoradiograms represent a
nested RT-PCR of RNAs from the indicated tissues of hGH/P1 line, 809C.
Control RNAs include wild-type brain and pituitary samples. The
amplifications generated end-labeled cDNA products specific to
hGH-N (top panel), hCS-A (middle panel), and
mouse actin (bottom panel) mRNAs. The results showed
strong hGH-N and hCS-A signals limited to the pituitary and placenta,
respectively, and weak signals in the brain, testes, and ovary.
WT, wild type.
|
|
Sublocalization of hCS Transgene Expression within the hGH/P1 Mouse
Placenta--
In prior studies we have demonstrated by
immunohistochemical staining the co-localization of hGH and mGH
expression in pituitary somatotrope cells of transgenic lines carrying
the hGH-N gene linked to the LCR (11). A similar study was carried out
to identify the site of hCS expression in the placenta of hGH/P1
transgenic mice. The mouse placenta is composed of a fetal portion and
a maternal portion. The fetal portion can be divided three regions: labyrinth, spongiotrophoblast, and trophoblast giant cells (Figs. 6, A and B).
In situ histohybridization with 33P-labeled
antisense RNA probes demonstrated that hCS-A mRNA was confined to
the labyrinth of P1 transgenic mouse placentas. Control studies with
the 33P-labeled sense probes and stains of wild type
placentas were all negative (Figs. 6, C and D).
By high power magnification, the positive cells in the labyrinth were
mononuclear, of moderate size, elongated, and usually located adjacent
to the maternal blood sinuses (Figs. 6, E and F).
There was some heterogeneity of expression levels among positive cells.
This was best seen by variation of signal strength on dark field
analyses. The morphology, location, and distribution of the positive
cells all suggested that they represented mononuclear labyrinthine
trophoblast cells.

View larger version (141K):
[in this window]
[in a new window]
|
Fig. 6.
hCS-A expression in the hGH/P1 mice is
localized to cells lining the maternal blood sinuses within the
labyrinthine region of the fetal placental. A, in
situ histohybridization of an hGH/P1 transgenic mouse placenta at
embryonic day 16.5 with an antisense [33P]hCS-A
riboprobe; bright field view. The large white arrows point
to the trophoblast giant cells, which are located between maternal
(left) and fetal (right) segments of the
placenta. The small black arrows within the fetal section of
the placenta mark the interface between spongiotrophoblast
(left) and labyrinthine (right) trophoblast
layers. B, dark field view of the same study and same field
as in A. The pink granules, representing the
33P-labled antisense hybridization signal, are limited to
the labyrinthine area. C, dark field view of a serial
section of hGH/P1 mouse placenta (as in A) incubated with a
sense [33P]hCS-A riboprobe. No signal was detected in
this negative control. D, dark field view of a section of a
nontransgenic, wild-type mouse placenta hybridized with the antisense
[33P] hCS-A riboprobe (as in B). No signal was
detected in this negative control. E, high power dark field
view of the labyrinthine area of an hGH/P1 mouse placenta hybridized
with the antisense [33P]hCS-A riboprobe. The white
arrows point to the hCS-A antisense probe signals (pink
cytoplasmic granules). These positive cells are located adjacent to the
maternal blood sinuses (s) containing red blood cells (400X
magnification). F, bright field view of E. The
cells expressing hCS-A contain the black grains.
|
|
 |
DISCUSSION |
Previous studies have demonstrated that expression of the hGH-N
transgene is dependent on remote regulatory elements. These elements
were originally identified as a set of DNaseI HS in pituitary chromatin
located from 14.5 to 32 kb 5' to the hGH gene cluster. Subsequent
functional analyses demonstrated that these elements were able to
overcome site of integration position effects and establish
autonomously regulated chromatin domains in mouse pituitary chromatin.
The activated hGH-N transgene was expressed at consistent and uniform
levels that were comparable to that of endogenous mouse GH. Based on
their ability to impart copy number dependence on the hGN-N transgene,
these elements fulfilled the criteria for LCR action (14, 25).
Genes in a cluster can compete with each other for LCR elements, and
such competition can constitute an essential aspect of their normal
developmental control. This is well illustrated in the human -globin
gene cluster in which the normal developmental silencing of the fetal
-globin gene is dependent on the presence of the adult-specific
-globin gene in cis (reviewed in Ref. 24) (25). Thus an
essential step in the characterization of expression patterns of genes
and establishing their mechanisms of control is to determine their
expression profiles when they are in the native configuration of their
family cluster. In the present studies, we introduced a large human DNA
fragment containing four members of the hGH gene family along with an
extensive segment of 5'-flanking region encompassing all five HS of the
LCR into the mouse genome. Analysis of hGH-N expression revealed that
five of five hGH/P1 lines expressed hGH-N in the pituitary at levels
correlating with transgene copy number. The levels of
expression/transgene copy for these lines were tightly grouped and were
comparable (34-96%) to the level of endogenous mGH. This is quite
similar to the levels of expression observed when the hGH-N gene with
contiguous LCR elements is introduced into the mouse genome in the
absence of the rest of the cluster (10). In both cases the transgenic
mice grew normally (i.e. no gigantism), suggesting that
there was no significant ectopic, unregulated hGH-N expression and that
the pituitary expression was under normal physiologic regulation. Thus
comparison of the present report with our prior studies allows us to
conclude that the expression of the hGH-N transgene linked to the LCR
is insertion site-independent, copy number-dependent, and
pituitary-specific whether isolated or in its native gene cluster environment.
The hGH gene cluster contains a set of placentally expressed genes
whose expression patterns are distinct and mutually exclusive from the
linked and structurally related hGH-N gene. When a 15-kb transgene
fragment containing the hCS-A gene with 5.4 kb of 5'-flanking sequences
and 7.2 kb of 3'-flanking sequences were tested for expression in a
transgenic assay, the placental expression of hCS-A was sporadic and
variable from line to line because of site of integration effects. Of
the six lines carrying this transgene, two lines expressed hCS-A at low
levels, two at trace levels, and two did not express hCS-A at all (10).
This weak and erratic expression profile was reminiscent of hGH-N
transgene expression in the absence of the LCR (10). A common
dependence on LCR function was further suggested by the observation
that HSIII and HSV of the GH LCR HS are present in both placental and
pituitary chromatin. Taken together these data suggested that the hCS-A
gene, like the linked and closely related hGH-N, was dependent upon LCR
function for activation.
In contrast to the erratic expression profile of the hCS-A transgene
lacking LCR elements seen in prior studies (10), five of five mouse
lines carrying the hGH/P1 transgene in the present study expressed
hCS-A in the placenta. Furthermore, the levels of hCS-A mRNA
expression/transgene copy number were highly reproducible (2-fold
range) for four of the five lines. The remarkably consistent expression
of the hCS-A gene in the context of the hGH/P1 transgene supports a
role for the remote 5'-flanking region LCR elements in establishing a
transcriptionally productive domain for the hCS-A gene in the placenta.
The consistent activation of the hCS-A gene in the context of the
hGH/P1 transgene is surprising from an evolutionary viewpoint. Both the
structure and composition of the GH gene family and the structure and
function of the placenta have diverged between mouse and man. The
multiple evolutionary rounds of gene duplication that have given rise
to a five member GH/CS cluster in humans have not occurred in the
rodent lineage. Instead, the GH-related but much more divergent
prolactin gene (26) has duplicated in the mouse, and most of these
multiple prolactin-related genes are expressed in the mouse placenta
(27, 28). It is not clear whether the function(s) of hCS in primates
and these prolactin-related hormones in rodents are similar. There is
also, at this time, no evidence to support an LCR linked to the single
mGH gene locus.2 Thus,
whatever transcriptional factors are acting on the hGH/P1 transgene to
activate the hCS locus in a consistent manner in the mouse placenta
must have been conserved despite this divergence between mouse and
primate at the GH gene locus.
The structures of the mouse and human placenta present fundamental
similarities and important distinctions (29). The placentas in both
species belong to the deciduate group in that they both contain fetal
and maternal portions. However, the details of their structures and
endocrine functions differ significantly. The mouse placenta is
labyrinthine, whereas the human placenta is villous (30). The murine
labyrinthine and human villous areas of the respective placentas are
the sites at which nutrients and gas exchanges occur between fetal and
maternal blood. The maze-like labyrinthine layer of the mouse placenta
is composed of anastomosing cords or plates of trophoblasts. These
trophoblasts are in direct contact with the maternal blood circulating
in the maternal blood sinuses. In this respect the murine labyrinthine
trophoblasts are analogous to the human syncytiotrophoblasts that line
the outer layer of the fetal placental villi and are also in direct contact with the maternal circulation. In the mouse, the labyrinthine trophoblasts form three layers separating the maternal blood from the
fetal blood, a single mononuclear cellular layer and two layers of a
trophoblast syncytium. The mononuclear cellular layer comes in direct
contact with maternal blood (31). In human placentas, hCS-A is
expressed in syncytiotrophoblast cells that line the surface of the
villi and contact maternal blood. In the hGH/P1 transgenic mouse,
hCS-A-positive cells were mononuclear and lined the maternal blood
sinuses within the labyrinth. Thus we conclude that the site of hCS-A
transgene expression in the trophoblasts cells lining the maternal
blood sinuses in the labyrinth of the mouse placenta is functionally
analogous to its natural site of expression in the human placenta.
Overlying the murine labyrinth is the spongiotrophoblast layer (Fig.
6A). The outermost cells in this layer are the trophoblast giant cells that form the interface with maternal decidua. In the
present studies, in situ hybridization showed that hCS-A
expression was limited to the labyrinth of transgenic mouse placenta.
In contrast, the mouse prolactin-related genes, PL-1 and PL-2, are expressed in the trophoblast giant cells (27, 28). The prolactin-like proteins, proliferin and proliferin-related protein, are expressed in
giant cells and/or spongiotrophoblast cells (32-37). These data indicate that the cell-specific expression of hCS-A in hGH/P1 transgenic mice may functionally parallel the site of hCS-A expression in human placenta and is clearly distinct from the sites of expression of the prolactin gene family in mouse placenta.
An extensive survey of tissue RNA samples from hGH/P1 mice was carried
out to identify tissues in addition to pituitary and placenta that
express the transgene. Northern blot analysis demonstrated only
pituitary and placental expression of the transgenes. However, a more
sensitive RT-PCR approach revealed several additional sites. hGH-N was
expressed at trace levels in the brain in all hGH/P1 transgenic lines
and in testis, ovary, or spleen in a subset of lines. hCS-A expression
was detectable at trace levels in brain, testis, ovary, and kidney.
Recent studies have reported low levels of GH gene expression in the
rat brain (38) and GH and CS gene expression in human testis (39) and
ovary (40). These observations suggest that the low level "ectopic"
expression from the hGH/P1 transgene that we have observed may instead
reflect normal physiologic patterns of low level gene expression.
In conclusion, the present study established a remarkable parallel
between the expression of the hGH gene cluster in situ and
its expression from a large continuous transgene encompassing the
cluster and the full LCR. The data further extended the function of the
LCR to expression of the hCS genes in the placenta and established an
in vivo model system in which the component determinants of
LCR function in the pituitary and placenta can be further explored.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Debra Silberg and Francois
Boudreau of the Morphology Core, Center for Molecular Studies in
Digestive and Liver Disease for assistance in establishing the in
situ studies. We also thank Dr. John Richa and the Transgenic Core
of the University of Pennsylvania for generating the transgenic
founders. The assistance of Jessie Harper in assembly and finalization
of this manuscript is greatly appreciated. This work was supported by
NIH R01 HD25147 (N.E.C.).
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: 752B Clinical
Research Bldg., 415 Curie Blvd., Philadelphia, PA 19103 6144. E-mail: necooke@mail.med.upenn.edu.
2
Y. Ho, S. A. Liebhaber, and N. E. Cooke, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
hGH, human growth
hormone;
kb, kilobase(s);
hCS, human chorionic somatomammotropin;
HS, hypersensitivity;
LCR, locus control region;
MOPS, 4-morpholinepropanesulfonic acid;
RT, reverse transcription;
PCR, polymerase chain reaction;
bp, base pair(s);
PBS, phosphate-buffered
saline.
 |
REFERENCES |
| 1.
|
Chen, E. Y.,
Liao, Y.-C.,
Smith, D. H.,
Barrera-Saldaña, H. A.,
Gelinas, R. E.,
and Seeburg, P.
(1989)
Genomics
4,
479-497[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Cooke, N. E.,
and Liebhaber, S. L.
(1995)
Vitam. Horm.
50,
385-459[Medline]
[Order article via Infotrieve]
|
| 3.
|
McWilliams, D.,
and Boime, I.
(1980)
Endocrinology
107,
761-765[Abstract/Free Full Text]
|
| 4.
|
Walker, W. H.,
Fitzpatrick, S. L.,
Barrera-Saldaña, H. A.,
Resendez-Perez, D.,
and Saunders, G. F.
(1991)
Endocrine Rev.
12,
316-328[Abstract/Free Full Text]
|
| 5.
|
Liebhaber, S. A.,
Urbanek, M.,
Ray, J.,
Tuan, R. S.,
and Cooke, N. E.
(1989)
J. Clin. Invest.
83,
1985-1991
|
| 6.
|
MacLeod, J. N.,
Lee, A. K.,
Liebhaber, S. A.,
and Cooke, N. E.
(1992)
J. Biol. Chem.
267,
14219-14226[Abstract/Free Full Text]
|
| 7.
|
Lefevre, C.,
Imagawa, M.,
Dana, S.,
Grindlay, J.,
Bodner, M.,
and Karin, M.
(1987)
EMBO J.
6,
971-981[Medline]
[Order article via Infotrieve]
|
| 8.
|
Lipkin, S. M.,
Näär, A. M.,
Kalla, K. A.,
Sack, R. A.,
and Rosenfeld, M. G.
(1993)
Genes Dev.
7,
1674-1687[Abstract/Free Full Text]
|
| 9.
|
Hammer, R. E.,
Palmiter, R. D.,
and Brinster, R. L.
(1984)
Nature
311,
65-67[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Jones, B. K.,
Monks, B. R.,
Liebhaber, S. A.,
and Cooke, N. E.
(1995)
Mol. Cell. Biol.
15,
7010-7021[Abstract]
|
| 11.
|
Bennani-Baiti, I. M.,
Asa, S. L.,
Song, D.,
Iratni, R.,
Liebhaber, S. A.,
and Cooke, N. E.
(1998)
Proc Natl. Acad. Sci.U. S. A.
95,
10655-10660[Abstract/Free Full Text]
|
| 12.
|
Palmiter, R. D.,
and Brinster, R. L.
(1986)
Annu. Rev. Genet.
20,
465-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Forrester, W. C.,
Takegawa, S.,
Papayannopoulou, T.,
Stamatoyannopoulos, G.,
and Groudine, M.
(1987)
Nucleic Acids Res.
15,
10159-10177[Abstract/Free Full Text]
|
| 14.
|
Grosveld, F.,
van Assendelft, G. B.,
Greaves, D. R.,
and Kollias, G.
(1987)
Cell
51,
975-985[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Orkin, S. H.
(1990)
Cell
63,
665-672[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Bonifer, C.,
Vidal, M.,
Grosveld, F.,
and Sippel, A. E.
(1990)
EMBO J.
9,
2843-2848[Medline]
[Order article via Infotrieve]
|
| 17.
|
Bonifer, C.,
Hecht, A.,
Saueressig, H.,
Winter, D. M.,
and Sippel, A. E.
(1991)
J. Cell. Biochem.
47,
99-108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wang, Y.,
Macke, J. P.,
Merbs, S. L.,
Zack, D. J.,
Klaunberg, B.,
Bennett, J.,
Gearhart, J.,
and Nathans, J.
(1992)
Neuron
9,
429-440[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Higgs, D. R.
(1998)
Cell
95,
299-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Liebhaber, S. A.,
Wang, Z.,
Cash, F. E.,
Monks, B.,
and Russell, J. E.
(1996)
Mol. Cell. Biol.
16,
2637-2646[Abstract]
|
| 21.
|
Meyuhas, O.,
and Perry, R. P.
(1980)
Gene (Amst.)
10,
113-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Duncan, S. A.,
Manova, K.,
Chen, W. S.,
Hoodless, P.,
Weinstein, D. C.,
Bachvarova, R. F.,
and Darnell, J. E., Jr.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
7598-7602[Abstract/Free Full Text]
|
| 23.
|
Sternberg, N. L.
(1992)
Trends Genet.
8,
11-16[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Misra-Press, A., N. E.,
Cooke, N. E.,
and Liebhaber, S. A.
(1994)
J. Biol. Chem.
269,
23220-23229[Abstract/Free Full Text]
|
| 25.
|
Bulger, M.,
and Groudine, M.
(1999)
Genes Dev.
13,
2465-2477[Free Full Text]
|
| 26.
|
Cooke, N. E.,
and Baxter, J. D.
(1982)
Nature
297,
603-606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Hall, J.,
and Talamantes, F.
(1984)
J. Histochem. Cytochem.
32,
379-382[Abstract]
|
| 28.
|
Faria, T. N.,
Ogren, L.,
Talamantes, F.,
Linzer, D. I.,
and Soares, M. J.
(1991)
Biol. Reprod.
44,
327-331[Abstract]
|
| 29.
|
Benirschke, K.,
and Kaufmann, P.
(1995)
Pathology of the Human Placenta
, Springer-Verlag New York Inc., New York
|
| 30.
|
Ramsey, E. M.
(1982)
The Placenta: Human and Animal
, pp. 7-56, Praeger, New York, 111-113.
|
| 31.
|
Lamming, G. E.
(1994)
Marshall's Physiology of Reproduction
, 4th Ed., Vol. 3
, pp. 233-460, Chapman and Hall, London
|
| 32.
|
Muller, H.,
Ishimura, R.,
Orwig, K. E.,
Liu, B.,
and Soares, M. J.
(1998)
Biol. Reprod.
58,
45-51[Abstract/Free Full Text]
|
| 33.
|
Dai, G.,
Chapman, B. M.,
Liu, B.,
Orwig, K. E.,
Wang, D.,
White, R. A.,
Preuett, B.,
and Soares, M. J.
(1998)
Endocrinology
139,
5157-5163[Abstract/Free Full Text]
|
| 34.
|
Lin, J.,
Poole, J.,
and Linzer, D. I.
(1997)
Endocrinology
138,
5535-5540[Abstract/Free Full Text]
|
| 35.
|
Lee, S.-J.,
Talamantes, F.,
Wilder, E.,
Linzer, D. I. H.,
and Nathans, D.
(1988)
Endocrinology
122,
1761-1768[Abstract/Free Full Text]
|
| 36.
|
Yamaguchi, M.,
Ogren, L.,
Endo, H.,
Soares, M. J.,
and Talamantes, F.
(1994)
Biol. Reprod.
51,
1188-1192[Abstract]
|
| 37.
|
Linzer, D. I.,
and Fisher, S. J.
(1999)
Mol. Endocrinol.
13,
837-840[Free Full Text]
|
| 38.
|
Yoshizato, H.,
Fujikawa, T.,
Soya, H.,
Tanaka, M.,
and Nakashima, K.
(1998)
Endocrinology
139,
2545-2551[Abstract/Free Full Text]
|
| 39.
|
Untergasser, G.,
Kranewitter, W.,
Schwarzler, P.,
Madersbacher, S.,
Dirnhofer, S.,
and Berger, P.
(1997)
Mol. Cell. Endocrinol.
130,
53-60[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Schwarzler, P.,
Untergasser, G.,
Hermann, M.,
Dirnhofer, S.,
Abendstein, B.,
Madersbacher, S.,
and Berger, P.
(1997)
J. Clin. Endocrinol. Metab.
82,
3337-3341[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. P. Kimura, D. Sizova, S. Handwerger, N. E. Cooke, and S. A. Liebhaber
Epigenetic Activation of the Human Growth Hormone Gene Cluster during Placental Cytotrophoblast Differentiation
Mol. Cell. Biol.,
September 15, 2007;
27(18):
6555 - 6568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Shewchuk, Y. Ho, S. A. Liebhaber, and N. E. Cooke
A Single Base Difference between Pit-1 Binding Sites at the hGH Promoter and Locus Control Region Specifies Distinct Pit-1 Conformations and Functions.
Mol. Cell. Biol.,
September 1, 2006;
26(17):
6535 - 6546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Yoo, I. Cajiao, J.-S. Kim, A. P. Kimura, A. Zhang, N. E. Cooke, and S. A. Liebhaber
Tissue-Specific Chromatin Modifications at a Multigene Locus Generate Asymmetric Transcriptional Interactions
Mol. Cell. Biol.,
August 1, 2006;
26(15):
5569 - 5579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kremyanskaya and J. G. Monroe
Ig-Independent Ig{beta} Expression on the Surface of B Lymphocytes after B Cell Receptor Aggregation
J. Immunol.,
February 1, 2005;
174(3):
1501 - 1506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Kimura, S. A. Liebhaber, and N. E. Cooke
Epigenetic Modifications at the Human Growth Hormone Locus Predict Distinct Roles for Histone Acetylation and Methylation in Placental Gene Activation
Mol. Endocrinol.,
April 1, 2004;
18(4):
1018 - 1032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Jin, L. D. Norquay, X. Yang, S. Gregoire, and P. A. Cattini
Binding of AP-2 and ETS-Domain Family Members Is Associated with Enhancer Activity in the Hypersensitive Site III Region of the Human Growth Hormone/Chorionic Somatomammotropin Locus
Mol. Endocrinol.,
March 1, 2004;
18(3):
574 - 587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ozturk, A. Fresnoza, A. Savoie, H. W. Duckworth, and M. L. Duckworth
Defining Regulatory Regions in the Rat Prolactin Gene Family Locus Using a Large P1 Genomic Clone
Endocrinology,
November 1, 2003;
144(11):
4742 - 4754.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. McGuinness, C. Magoulas, A. K. Sesay, K. Mathers, D. Carmignac, J.-B. Manneville, H. Christian, J. A. Phillips III, and I. C. A. F. Robinson
Autosomal Dominant Growth Hormone Deficiency Disrupts Secretory Vesicles in Vitro and in Vivo in Transgenic Mice
Endocrinology,
February 1, 2003;
144(2):
720 - 731.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. de Jersey, D. Carmignac, T. Barthlott, I. Robinson, and B. Stockinger
Activation of CD8 T Cells by Antigen Expressed in the Pituitary Gland
J. Immunol.,
December 15, 2002;
169(12):
6753 - 6759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Li, K. R. Peterson, X. Fang, and G. Stamatoyannopoulos
Locus control regions
Blood,
October 16, 2002;
100(9):
3077 - 3086.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Shewchuk, S. A. Liebhaber, and N. E. Cooke
Specification of unique Pit-1 activity in the hGH locus control region
PNAS,
September 3, 2002;
99(18):
11784 - 11789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Madison, L. Dunbar, X. T. Qiao, K. Braunstein, E. Braunstein, and D. L. Gumucio
cis Elements of the Villin Gene Control Expression in Restricted Domains of the Vertical (Crypt) and Horizontal (Duodenum, Cecum) Axes of the Intestine
J. Biol. Chem.,
August 30, 2002;
277(36):
33275 - 33283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Shewchuk, N. E. Cooke, and S. A. Liebhaber
The human growth hormone locus control region mediates long-distance transcriptional activation independent of nuclear matrix attachment regions
Nucleic Acids Res.,
August 15, 2001;
29(16):
3356 - 3361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Elefant, N. E. Cooke, and S. A. Liebhaber
Targeted Recruitment of Histone Acetyltransferase Activity to a Locus Control Region
J. Biol. Chem.,
April 28, 2000;
275(18):
13827 - 13834.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|